Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the
efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe
AA. The study consists of 3 phases: a screening phase of up to 5 weeks, a treatment phase of
24 weeks, and a follow-up phase of 4 weeks. Study drug will be administered via intravenous
(IV) push weekly.